frequency-severity

Frequency
Severity

MEAN CHANGE FROM BASELINE IN MODERATE TO SEVERE VMS OVER 24 HOURS^1,7

Trial 1 Trial 2

VEOZAH 45 mg (n=174)

Placebo (n=175)

HOT FLASHES CUT IN HALF

by week 4 vs ~one-third with placebo^†

64% FEWER HOT FLASHES

by week 12 vs 45% with placebo^†

VEOZAH 45 mg (n=167)

Placebo (n=167)

HOT FLASHES CUT IN HALF

by week 4 vs ~one-third with placebo^†

64% FEWER HOT FLASHES

by week 12 vs 45% with placebo^†

With VEOZAH, help your patients reduce VMS interruptions day and night

MEAN CHANGE FROM BASELINE IN MODERATE TO SEVERE VMS OVER 24 HOURS^1,3,4

Trial 1 Trial 2

VEOZAH 45 mg (n=174)

Placebo (n=175)

REDUCED, ON AVERAGE, FROM

moderate/severe trending_flat mild/moderate

VEOZAH 45 mg (n=167)

Placebo (n=167)

REDUCED, ON AVERAGE, FROM

moderate/severe trending_flat mild/moderate

VEOZAH allows you to help your patients continue activity with less sweat and disruption

What really gets me about menopause is the hot flushes. Suddenly I'm turning red, and there's nothing I can do about it.